Q-omics provides the consensus-scored ANAPC13 profile across patient tissues and cancer cell-line models. ANAPC13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANAPC13 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANAPC13 protein abundance shows 21,416 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, HNSC, and CCRCC as cancer lineages where ANAPC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC13 survival associations across molecular data types. ANAPC13 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC13 RNA expression–survival associations across cancer types. High ANAPC13 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, UVM, KIRP, UCS and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANAPC13 RNA expression.
This table summarizes ANAPC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ANAPC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC13 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, LIHC and COAD. The HNSC box plot shows higher ANAPC13 RNA expression in tumor versus normal tissue (log2 FC = +1.163, t-test p < 0.001).
This table shows molecular features associated with ANAPC13 in patient tissues and cancer cell lines. In patient samples, ANAPC13 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANAPC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
